ArticleJournal of controlled release : official journal of the Controlled Release Society2012
Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 81 citations in OpenAlex.
- Nanocarrier-mediated targeting of chemotherapy-induced DPP4 enhances T cell infiltration and improves cancer immunochemotherapy.Bioactive materials · 2027Article
- What If Trojan Horse Nanoparticles Could Change the Game for HPV Gene-Targeted Therapies?Journal of medical virology · 2026Review
- Engineered exosomes from umbilical cord mesenchymal stem cells with pPB modification attenuate hepatic fibrosis via hepatic stellate cell targeting.Journal of translational medicine · 2026Article
- Review
- Bioinspired Natural Product Nanoplatforms for Precision Cancer Theranostics from Nature to Nanomedicine.International journal of nanomedicine · 2026Review
- In Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy.Nature communications · 2024Article
- Review
- Small-Sized Co-Polymers for Targeted Delivery of Multiple Imaging and Therapeutic Agents.Nanomaterials (Basel, Switzerland) · 2021Review
- Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based "combo" nanoagent together with PD-L1 blockade in reversing multidrug resistance.Journal of nanobiotechnology · 2021Article
- Efficient Anti-Glioma Therapy Through the Brain-Targeted RVG15-Modified Liposomes Loading Paclitaxel-Cholesterol Complex.International journal of nanomedicine · 2021Article
- Probing the biological obstacles of nanomedicine with gold nanoparticles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Article
- Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery.Theranostics · 2019Review
- Design, Synthesis and Characterization of Novel Co-Polymers Decorated with Peptides for the Selective Nanoparticle Transport across the Cerebral Endothelium.Molecules (Basel, Switzerland) · 2018Article
- Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging.ACS applied materials & interfaces · 2018Article
- The potential of multi-compound nanoparticles to bypass drug resistance in cancer.Cancer chemotherapy and pharmacology · 2017Review
- Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma.International journal of clinical and experimental medicine · 2015Article
- Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures.International journal of nanomedicine · 2015Review
- AEG-1 promoter-mediated imaging of prostate cancer.Cancer research · 2014Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Targeted nanoparticle-based delivery systems have been used extensively to develop effective cancer theranostics. However, how targeting ligands affect extravascular transport of nanoparticles in solid tumors remains unclear. Here, we show, using B16/F10 melanoma cells expressing melanocortin type-1 receptor (MC1R), that the nature of targeting ligands, i.e., whether they are agonists or antagonists, directs tumor uptake and intratumoral distribution after extravasation of nanoparticles from tumor vessels into the extravascular fluid space. Pegylated hollow gold nanospheres (HAuNS, diameter=40 nm) coated with MC1R agonist are internalized upon ligand-receptor binding, whereas MC1R antagonist-conjugated HAuNS remain attached on the cell surface. Transcellular transport of agonist-conjugated HAuNS was confirmed by a multilayer tumor cell model and by transmission electron microscopy. MC1R agonist- but not MC1R antagonist-conjugated nanoparticles exhibit significantly higher tumor uptake than nontargeted HAuNS and are quickly dispersed from tumor vessels via receptor-mediated endocytosis and subsequent transcytosis. These results confirm an active transport mechanism that can be used to overcome one of the major biological barriers for efficient nanoparticle delivery to solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.